![]() | |
Clinical data | |
---|---|
Other names | PC-945 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C38H37F3N6O3 |
Molar mass | 682.748 g·mol−1 |
Opelconazole (PC-945) is an experimental antifungal drug and the first triazole delivered via inhalation. [1] [2] [3] The drug is in Phase III and Phase II trials as of 2023. [4]
![]() | |
Clinical data | |
---|---|
Other names | PC-945 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C38H37F3N6O3 |
Molar mass | 682.748 g·mol−1 |
Opelconazole (PC-945) is an experimental antifungal drug and the first triazole delivered via inhalation. [1] [2] [3] The drug is in Phase III and Phase II trials as of 2023. [4]